ホームページ JAK/STAT JAK inhibitor - STAT inhibitor - Apoptosis related activator WP1066 For research use only.

WP1066

WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. WP1066 induces apoptosis. Phase 1.

WP1066化学構造

CAS No. 857064-38-1

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫あり
JPY 40500 国内在庫あり
JPY 448500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール：[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例（71）

製品安全説明書

現在のバッチを見る： 純度： 99.97%
99.97

WP1066関連製品

シグナル伝達経路

JAK Signaling Pathways

JAKシグナル伝達経路

JAK阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
human MM1 cells Function assay 24-72 h Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay, ic50=1.2 μM 22036213
human U266 cells Function assay 24-72 h Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay, IC50=1.5 μM 22036213
human OCI-My4 cells Function assay 24-72 h Antitumor activity against human OCI-My4 cells after 24 to 72 hrs by MTT assay, IC50=1.8 μM 22036213
human 30M cells Cytotoxic assay 8 days Cytotoxicity against human 30M cells assessed as cell viability after 8 days by Alamar Blue assay, IC50=1.8 μM 24900612
human 73M cells Cytotoxic assay 8 days Cytotoxicity against human 73M cells assessed as cell viability after 8 days by Alamar Blue assay, IC50=2.1 μM 24900612
human U373MG cells Function assay 24-72 h Antitumor activity against human U373MG cells after 24 to 72 hrs by MTT assay, IC50=3.7 μM 22036213
human U87MG cells Function assay 24-72 h Antitumor activity against human U87MG cells after 24 to 72 hrs by MTT assay, IC50=5.6 μM 22036213
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. WP1066 induces apoptosis. Phase 1.
特性 Similar to its parent compound AG490, WP1066 inhibits the phosphorylation of JAK2, but unlike AG490, WP1066 also degraded JAK2 protein.
Targets
JAK2 [1]
(HEL cells)		 STAT3 [2]
(HEL cells)
2.3 μM 2.43 μM
In Vitro
In vitro WP1066 markedly inhibits the growth of HEL cells carrying the JAK2 V617F mutant isoform in a dose-dependent manner with IC20, IC50 and IC80 of 0.8, 2.3 and 3.8 μM. WP1066 at concentrations of 0.5, 1.0, 2.0, 3.0, or 4.0 μM inhibits the phosphorylation of JAK2, STAT3, STAT5, and ERK1/2 without affecting the phosphorylation of JAK1 and JAK3 in erythroid leukemia HEL cells that express the JAK2 V617F isoform. [1] WP1066 at concentrations ranging from 0.5 to 3.0 μM inhibits the proliferation of AML colony-forming cells obtained from patients and that of the AML cell lines OCIM2 and K562 in a dose-dependent manner. WP1066 at concentrations of 0.5, 1.0, 2.0, 3.0, or 4.0 μM dose-dependently decreases JAK2 and pJAK2 protein levels as well as downstream phosphorylation levels of STAT3, STAT5, and AKT in OCIM2 and K562 cells. WP1066 at concentrations of 2 μM inhibits OCIM2 cell multiplication by inducing accumulation of cells at the G0-G1 phase of the cell cycle. WP1066 at concentrations of 1, 2, or 3 μM induces apoptosis in both OCIM2 and K562 cells in a dose-dependent fashion by activating procaspase-3 and cleaving PARP. [3] WP1066 at concentrations of 5 μM prevents the phosphorylation of STAT3, and at concentrations of 2.5μM WP1066 significantly inhibits cell survival and proliferation in Caki-1 and 786-O renal cancer cells. WP1066 at concentrations of 5 μM suppresses HIF1α and HIF2α expression and VEGF production in Caki-1 and 786-O renal cancer cells. [4]
細胞実験 細胞株 HEL cells carrying the JAK2 V617F mutant isoform, HL60, K562, Raji, PEER, CMK, TM and RHN cells
濃度 0 - 6 μM
反応時間 72 hours
実験の流れ The 3, [4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium (MTT) assay is done using an MTT-based cell proliferation/cytotoxicity assay system. Briefly, fresh low-density peripheral blood cells and various cell lines at the logarithmic phase of their growth are washed twice in RPMI 1640 containing 10% FCS and counted in a hemocytometer. Cell viability is assessed by the trypan blue (0.1%) staining method. Equal numbers of viable cells (5 × 104 per well) are incubated in a total volume of 100 μL of RPMI 1640 supplemented with 10% FCS alone or with WP1066 at increasing concentrations; the incubations are continued for up to 72 h in 96-well flat-bottomed plates at 37 °C in a humidified 5% CO2 atmosphere. Experiments for each condition are done in triplicate. After incubation, 20 μL of CellTiter96 One Solution Reagent are added to each well. The plates are then incubated for an additional 60 min at 37 °C in a humidified 5% CO2 atmosphere. Immediately after incubation, absorbance is read using a 96-well plate reader at a wavelength of 490 nm.
実験結果図 Methods Biomarkers 結果図 PMID
Western blot p-STAT3 / STAT3 / p-ERK / ERK 20461084
Cell viability Cell viability 28496056
Immunofluorescence N-cadherin / E-cadherin / Vimentin / β-catenin 26690371
In Vivo
In Vivo WP1066 orally administrated at dose of 40 mg/kg once daily for 19 days significantly inhibits the tumours growth in Caki-1 xenograft mice, with decreased immunostaining of phosphorylated STAT3 and reduced length of CD34-positive vessels. [4]
動物実験 動物モデル Caki-1 xenograft mice
投与量 40 mg/kg
投与経路 Orally administrated
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04334863 Completed
Brain Tumor|Medulloblastoma|Brain Metastases
Emory University|CURE Childhood Cancer Inc.|Peach Bowl LegACy Fund
 May 4 2020 Phase 1

化学情報

分子量 356.22 化学式

C17H14BrN3O
CAS No. 857064-38-1 SDF Download WP1066 SDFをダウンロードする
Smiles CC(C1=CC=CC=C1)NC(=O)C(=CC2=NC(=CC=C2)Br)C#N
保管

In vitro
Batch:

DMSO : 71 mg/mL ( (199.31 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

mg/kg g μL 匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: WP1066を買う | WP1066 ic50 | WP1066供給者 | WP1066を購入する | WP1066費用 | WP1066生産者 | オーダーWP1066 | WP1066化学構造 | WP1066分子量 | WP1066代理店